Earnings ·
TELA Bio reports Q3 revenue of $19.0M, reduced operating loss by 21% to $7.3M
TELATELA Bio, Inc.
TELA Bio reported third-quarter 2026 revenue of $19.0 million, an 8% decrease from the prior-year period, driven by lower OviTex PRS volumes partially offset by international growth. The company reduced its sequential operating loss by 21% to $7.3 million and cut Adjusted EBITDA loss by 55% to $3.4 million. Management announced a strategic cost reduction initiative aimed at lowering annual operating expenses by $17.0 million to extend the cash runway into 2028. Additionally, TELA Bio regained compliance with Nasdaq's minimum bid price requirement and received FDA 510(k) clearance for its Liora Monofilament Scaffold. The company operates in the medical technology sector, providing soft-tissue reconstruction solutions.